/Resource Pages/Recommended Publications/Recommended Reading/RNAi

Quick Links:

transEDIT CRISPR-Cas9 product overview shERWOOD-UltramiR shRNA product overview MGC premier cDNA product overview MGC premier ORF product overview Yeast knockout collections product overview Mutagenesis, custom cloning, lentiviral packaging, lncRNA knockdown and ssODN templates resources Vector maps and sequences for CRISPR, RNAi and Gene Expression vectors Contact Us about products for your gene analysis and gene editing experiments

Click the tabs below to view a list of peer-reviewed publications citing successful use of transOMIC technologies products.

 shERWOOD-UltramiR shRNA Design + Optimized shRNA Processing = Superior Knockdown!

Lentiviral, inducible lentiviral and retroviral vector options
with a choice of promoters for optimal expression in your target cell lines!


Related to RNAi technology
Read how the authors below used our shERWOOD-UltramiR shRNA targeting lncRNA.
Read how the authors below used our shERWOOD-UltramiR shRNA targeting lncRNA.
Read how the authors below used our shERWOOD-UltramiR shRNA targeting lncRNA.
Read how the authors in this paper used our inducible shRNA for STIM1 to "elucidate the role of Ca2+ signaling in mammalian neuronal development"

Read how the authors below used our DGAT1 shRNA to "provide a functional role to macrophage lipid droplets in host defense and open new avenues for developing host-directed therapies against tuberculosis."

Read how the authors below used our human and mouse MYCN shRNA to "report that an enriched glutaminolysis gene signature is associated with MYCN amplification in children with Neuroblastoma."

Read below how the researchers used our retroviral shRNA to "implicate REV-ERBβ in the control of skeletal muscle metabolism and energy expenditure and suggest that development of REV-ERBα versus REV-ERBβ selective ligands may have therapeutic utility in the treatment of metabolic syndrome."

Read how these researchers used our shRNA to create knockdown cell lines in their pursuit to "provide pre-clinical rationale for targeting PRMT5 using small molecule inhibitors in the treatment of leukemias harboring MLL-rearrangements."
Read how the authors below used our MYCN shRNA to "suggest that the metabolic modulation and ROS (reactive oxygen species) augmentation could be used as novel strategies in treating NBL (Neuroblastoma) and other MYC-driven cancers."
Read how the authors used our Atoh1 and Jak2 shRNA to determine that "...inhibiting Jak2-mediated tyrosine 78 phosphorylation could provide a viable therapy for medulloblastoma."
Read how the authors used our shERWOOD Epigenetics-related genes library to screen for druggable targets related to Glioblastoma.
Read how the researchers below used our DUX4 and non-targeting retroviral shRNA to "demonstrate that FRG1 is a direct DUX4 transcriptional target uncovering a novel regulatory circuit contributing to Facioscapulohumeral muscular dystrophy (FSHD)"
Read how the authors below used our NFE2L2 and control shRNA to "show the effectiveness and molecular mechanism of artesunate treatment (anti-malarial drug) on head and neck cancer (HNC)"
Read how the authors used our CISD2 shRNA to study how "CISD2 mRNA was significantly upregulated in lung adenocarcinoma (ADC) samples".
See how the authors below used our Glis3 inducible shRNA to "uncover a mechanism by which GLIS3 deficiency causes neonatal hypothyroidism and prevents goiter development."
See how the authors below used our CPT1a shRNA to study adaptive immune responses related to Non-alcoholic fatty liver disease and Hepatocellular carcinoma.
Read below how the authors used our mouse Ikzf4 retroviral shRNA to study LAG3 as it relates to autoimmune diseases.
Read how the researchers below used a custom shRNA pool to identify "ATP-buffering, mitochondrial creatine kinase CKMT1 as a metabolic dependency in EVI1-positive (acute myeloid leukemia) AML".
Read how the researchers below used our retroviral shRNA to demonstrate that "CREM prevents production of IL-2, thereby contributing to T-cell exhaustion and chronic viral infection."
Read how these researchers used our shRNA to "investigate the molecular mechanisms of the high IGF-1 level linking diabetes and cancers, which is a risk factor."
Read how the authors below used our mouse PGRN and human PGRN retroviral shRNAs to explore osteoclastogenesis which may uncover new therapies for osteoporosis.
Read below how these researchers used our retroviral NOTCH1 shRNA to "present a novel clinical and functional significance of NOTCH1 alterations in early stage tongue squamous cell carcinoma (TSCC)"
Read how the authors of this paper used our human Bax and Bak shRNA to explore targeting glutamine metabolism in Neuroblastoma and Ewing's sarcoma as a therapeutic strategy.
See how the authors used one of our Ametrine labeled retroviral shRNA to study the effects of Lef-1 expression on T follicular helper cells.
See how the authors of this paper used our SNMA1 shRNA to help "provide insight into the mechanism of FAN1 in ICL repair and demonstrate that the Fan1 mouse model effectively recapitulates the pathological features of human FAN1 deficiency."
See how the authors of this publication used our inducible shRNA to gain insight into breast cancer bone metastasis related to "mechanistic regulation and linkage of the ROR1-HER3 and Hippo-YAP pathway"
See how the author of this paper used our shRNA clones to present data that identifies the previously uncharacterized IGF1-RIT1-Akt-Sox2 signaling pathway as a key component of neurogenic niche sensing, contributing to the regulation of neural stem cell homeostasis.
Read how the author of this publication commented on his success with our shRNA against Mouse c-jun.
Read how Dr. Tiemo Klisch from Baylor College of Medicine understood the potency of our shERWOOD UltramiR shRNA reagents, but he needed the shRNAs delivered in custom lentiviral vector expressing a red fluorescent protein in order to fit with his experimental work flow.
Read how the authors used our OMNIfect transfection reagent with GCGR shRNA to "provide experimental evidence that hyperglucagonemia in type 2 diabetes promotes colon cancer progression via GCGR-mediated regulation of AMPK and MAPK pathways."
Read how this customer used our shERWOOD Epigenetics related genes library to shuttle into an inducible retroviral vector and the perform parallel in vitro and in vivo functional screening related to glioblastoma target discovery.